Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Egger, M; Gornicec, M; Wölfler, A; Lembeck, AL; Tinchon, C; Maderdonner, M; Prattes, J.
Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria.
Med Mycol. 2022; 60(9):
Doi: 10.1093/mmy/myac061
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Egger Matthias Florian
-
Prattes Jürgen
- Co-Autor*innen der Med Uni Graz
-
Wölfler Albert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Since the broad implementation of ibrutinib therapy, an increasing number of studies have been reported on invasive fungal infections (IFI) associated with ibrutinib administration. We conducted a retrospective cohort study in three hospitals in south-east Austria in order to assess the local epidemiology of ibrutinib associated IFIs. A total of 113 patients with underlying hematological malignancy were included in the study. During the study period, a single IFI episode was observed, which corresponds to an IFI incidence of 2.3 cases per 100 person years (95% CI: 0.12-11.47). IFIs during ibrutinib therapy seem to be a rare event in case of absent additional risk factors for IFIs.
- Find related publications in this database (using NLM MeSH Indexing)
-
Adenine - analogs & derivatives
-
Animals - administration & dosage
-
Antifungal Agents - therapeutic use
-
Austria - epidemiology
-
Hematologic Neoplasms - complications, drug therapy, veterinary
-
Humans - administration & dosage
-
Incidence - administration & dosage
-
Invasive Fungal Infections - complications, drug therapy, epidemiology, veterinary
-
Piperidines - administration & dosage
-
Retrospective Studies - administration & dosage
- Find related publications in this database (Keywords)
-
small molecule kinase inhibitor
-
ibrutinib
-
hematologic malignancy
-
invasive fungal infection